Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
26.44
+0.77 (3.00%)
At close: Jan 30, 2026, 4:00 PM EST
26.45
+0.01 (0.04%)
After-hours: Jan 30, 2026, 4:10 PM EST
Enliven Therapeutics Market Cap
Enliven Therapeutics has a market cap or net worth of $1.57 billion as of January 30, 2026. Its market cap has increased by 41.78% in one year.
Market Cap
1.57B
Enterprise Value
1.09B
1-Year Change
41.78%
Ranking
Category
Stock Price
$26.44
Market Cap Chart
Since February 24, 2023, Enliven Therapeutics's market cap has increased from $974.02M to $1.57B, an increase of 61.16%. That is a compound annual growth rate of 17.66%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 30, 2026 | 1.57B | 71.75% |
| Dec 31, 2025 | 913.95M | -16.86% |
| Dec 31, 2024 | 1.10B | 92.74% |
| Dec 29, 2023 | 570.37M | -41.44% |
| Feb 24, 2023 | 974.02M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Tyra Biosciences | 1.64B |
| Immunocore Holdings | 1.64B |
| Oculis Holding AG | 1.64B |
| Celldex Therapeutics | 1.63B |
| Monte Rosa Therapeutics | 1.63B |
| Agios Pharmaceuticals | 1.60B |
| Precigen | 1.59B |
| Biohaven | 1.57B |